YKL-5-124
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


YKL-5-124
Description:
YKL-5-124 is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status[1].UNSPSC:
12352005Hazard Statement:
H302, H315, H319, H335Target:
CDKType:
Reference compoundRelated Pathways:
Cell Cycle/DNA DamageApplications:
Neuroscience-NeuromodulationField of Research:
CancerAssay Protocol:
https://www.medchemexpress.com/ykl-5-124.htmlPurity:
99.53Solubility:
DMSO : 100 mg/mL (ultrasonic)Smiles:
CC1(C)N(C(N[C@@H](C2=CC=CC=C2)CN(C)C)=O)CC3=C1NN=C3NC(C4=CC=C(NC(C=C)=O)C=C4)=OMolecular Formula:
C28H33N7O3Molecular Weight:
515.61Precautions:
H302, H315, H319, H335References & Citations:
[1]Olson CM, et al. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chem Biol. 2019 Jun 20;26 (6) :792-803.e10.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
No Development ReportedIsoform:
CDK2; CDK7; CDK9Citation 01:
BioRxiv. 2023 Apr 23.|bioRxiv. 2024 Dec 10:2024.12.09.627542.|bioRxiv. 2025 March 19.|Cell Death Discov. 2025 Mar 4;11 (1) :86.|Cell Discov. 2022 Oct 6;8 (1) :102.|EMBO J. 2025 Sep 8.|Int J Biol Sci. 2024 Aug 19;20 (11) :4513-4531.|Int J Mol Sci. 2023 Apr 10;24 (8) :7009.|iScience. 2024 May 16.|iScience. 2025 Nov 4;28 (12) :113925.|J Biomed Sci. 2022 Feb 14;29 (1) :13.|J Cancer Res Clin Oncol. 2023 Jul;149 (8) :5255-5263.|mBio. 2025 Dec 10;16 (12) :e0289825.|Res Sq. 2024 Jul 29.|Adv Sci (Weinh) . 2024 Dec 10:e2413103.|Cell. 2025 Oct 30;188 (22) :6301-6316.e29.CAS Number:
[1957203-01-8]
